Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS
July 02, 2019 16:01 ET
|
Arbutus Biopharma Corporation
- Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics - Runway extended with non-dilutive capital WARMINSTER, Pa., July 02,...
Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
June 17, 2019 07:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the...
Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 06, 2019 16:01 ET
|
Arbutus Biopharma Corporation
Top-line safety and efficacy results from an interim analysis of the initial Phase 1a/1b clinical trial of AB-506, a proprietary oral capsid inhibitor, expected in July 2019 Conference Call and...
Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
March 07, 2019 16:01 ET
|
Arbutus Biopharma Corporation
- Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg - Ongoing analyses of AB-452, a novel orally-available...
Arbutus Appoints Dr. Frank Torti as Chairman of its Board of Directors
November 26, 2018 16:41 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus Reports 2018 Third Quarter Financial Results and Provides Corporate Update
November 07, 2018 16:01 ET
|
Arbutus Biopharma Corporation
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug Administration (FDA) and the...
Arbutus Names New Members to its Board of Directors
October 22, 2018 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that James...
Arbutus Provides Update on HBV Development Programs and Announces Appointment of Dr. Gaston Picchio as Chief Development Officer
October 09, 2018 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced a change...
M2 Compliance to Sponsor MicroCap Conference in New York at Essex House
September 29, 2018 12:42 ET
|
M2 Compliance
NEW YORK, NY, Sept. 29, 2018 (GLOBE NEWSWIRE) -- M2 Compliance ("M2") (www.m2compliance.com), a world-leading SEC registered filing agent and full-service financial printer, announced it would be...
Arbutus to Participate at the 2018 B. Riley FBR Healthcare Conference
August 28, 2018 08:30 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....